TLPPF Telix Pharmaceuticals Ltd
Price Chart
Executive Summary
Telix Pharmaceuticals announced that the FDA has accepted the resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara), a PET imaging agent for glioma, with a PDUFA goal date of September 11, 2026. This is a significant milestone in the company's pipeline.
Actionable Insight
The FDA acceptance of the NDA for Pixclara is a significant regulatory milestone that increases the likelihood of approval by the PDUFA date. This could lead to commercialization in a high-unmet-need oncology indication, potentially driving revenue growth. Traders should monitor for any updates on the approval process and consider the potential market opportunity for glioma imaging.
Key Facts
- FDA accepted the resubmitted NDA for TLX101-Px (Pixclara) for the imaging of glioma
- PDUFA goal date set for September 11, 2026
- TLX101-Px has been granted Orphan Drug and Fast Track designations by the FDA
- Approval would fulfill an unmet medical need for characterizing recurrent or progressive glioma
- No revenue contribution from TLX101-Px is included in Telix's FY 2026 financial guidance
Financial Impact
Potential future revenue from a new oncology product, though not included in current guidance
Risk Factors
- Approval not guaranteed by PDUFA date
- No revenue contribution included in current financial guidance
- Potential competition in the radiopharmaceutical space
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-024572 |
| Document: a20260410pixclarandaacce.htm | 0001628280-26-024572 |
| Document: 0001628280-26-024572-index-headers.html | 0001628280-26-024572 |
| Document: 0001628280-26-024572-index.html | 0001628280-26-024572 |
| Document: 0001628280-26-024572.txt | 0001628280-26-024572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 21, 2026
22d ago
|
6-K
| $9.75 $9.20 | ▼ −5.64% | ▼ −7.30% | $9.52 (−2.36%) |
|
May 18, 2026
25d ago
|
3
| $9.75 $9.75 | · 0.00% | ▼ −2.30% | $9.52 (−2.36%) |
|
May 18, 2026
25d ago
|
3
| $9.75 $9.75 | · 0.00% | ▼ −2.30% | $9.52 (−2.36%) |
|
May 18, 2026
25d ago
|
3
| $9.75 $9.75 | · 0.00% | ▼ −2.30% | $9.52 (−2.36%) |
|
Apr 21, 2026
7w ago
|
6-K
| $10.50 $10.25 | ▼ −2.38% | ▼ −2.44% | $9.52 (−9.33%) |
|
Apr 14, 2026
8w ago
|
6-K
| $10.57 $10.50 | ▼ −0.66% | ▼ −2.06% | $9.52 (−9.93%) |
|
Apr 13, 2026
8w ago
|
6-K
| $10.57 $10.50 | ▼ −0.66% | ▼ −2.06% | $9.52 (−9.93%) |
|
Apr 10, 2026
9w ago
|
6-K
| $9.70 $10.50 | ▲ +8.25% | ▲ +3.74% | $9.52 (−1.86%) |
|
Apr 9, 2026
9w ago
|
6-K
| $9.70 $10.68 | ▲ +10.10% | ▲ +6.92% | $9.52 (−1.86%) |
|
Apr 7, 2026
9w ago
|
6-K
| $9.00 $10.57 | ▲ +17.44% | ▲ +12.12% | $9.52 (+5.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access